Contact Us | Print Page | Sign In | Register
News & Press: CMSC Industry News for MS (INforMS)

CMSC INforMS: Avonex and Plegridy Label Updates

Tuesday, March 31, 2020  
Posted by: Elizabeth Porco
Share |

The Plegridy (peginterferon beta-1a) Prescribing Information and the Avonex (interferon beta-1a) Prescribing Information was updated in the late afternoon on March 27, 2020. The following sections were changed:


·         Sections 8.1 and 8.2


·         Section 2.2

·         Section 3

·         Section 4

·         Section 6.2

·         Section 8.1 and 8.2

·         Section 11

Please see the Avonex and Plegridy Full Prescribing Information below.



CMSC Disclaimer
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275